Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Share Price Crosses Above 200-Day Moving Average - Time to Sell?

Key Points

• Fresenius Medical Care shares crossed above their 200-day moving average, reaching $23.24 before last trading at $23.07, while volume totaled 715,624 shares.
• Analyst sentiment remains cautious: six analysts rate the stock Hold and five rate it Sell, producing an average “Reduce” rating and a $23.57 target price. BNP Paribas Exane downgraded the stock to Underperform with a $19.90 target.
• The company exceeded quarterly expectations, reporting $0.66 EPS versus a $0.62 consensus estimate and $5.55 billion in revenue versus $5.48 billion expected; institutional investors own 8.37% of the shares.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) shares crossed above its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $23.12 and traded as high as $23.24. Fresenius Medical Care AG & Co. KGaA shares last traded at $23.07, with a volume of 715,624 shares traded.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the company. Weiss Ratings reiterated a "hold (c)" rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Tuesday, August 4th. Sanford C. Bernstein increased their target price on Fresenius Medical Care AG & Co. KGaA from $25.50 to $25.80 and gave the company a "market perform" rating in a report on Thursday, August 6th. Citigroup restated a "neutral" rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Friday, July 17th. BNP Paribas Exane lowered Fresenius Medical Care AG & Co. KGaA from a "neutral" rating to an "underperform" rating and set a $19.90 price target on the stock. in a research note on Tuesday, July 28th. Finally, Truist Financial set a $25.00 price target on Fresenius Medical Care AG & Co. KGaA in a research report on Wednesday, August 5th. Six investment analysts have rated the stock with a Hold rating and five have issued a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of "Reduce" and an average target price of $23.57.

Fresenius Medical Care AG & Co. KGaA Trading Down 0.9%

The stock has a market capitalization of $12.39 billion, a PE ratio of 11.95, a P/E/G ratio of 4.32 and a beta of 0.77. The company's 50 day moving average price is $23.94 and its two-hundred day moving average price is $23.12. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.07 and a quick ratio of 0.75.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.04. The company had revenue of $5.55 billion during the quarter, compared to analysts' expectations of $5.48 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.83% and a return on equity of 9.28%. As a group, analysts expect that Fresenius Medical Care AG & Co. KGaA will post 2.25 earnings per share for the current year.

Institutional Investors Weigh In On Fresenius Medical Care AG & Co. KGaA

A number of large investors have recently made changes to their positions in FMS. Morgan Stanley increased its holdings in shares of Fresenius Medical Care AG & Co. KGaA by 47.2% in the fourth quarter. Morgan Stanley now owns 2,939,839 shares of the company's stock valued at $70,027,000 after purchasing an additional 942,497 shares during the last quarter. Pzena Investment Management LLC boosted its stake in Fresenius Medical Care AG & Co. KGaA by 2.0% during the first quarter. Pzena Investment Management LLC now owns 15,052,822 shares of the company's stock worth $339,592,000 after buying an additional 299,986 shares during the last quarter. Bank of America Corp DE boosted its stake in Fresenius Medical Care AG & Co. KGaA by 279.7% during the second quarter. Bank of America Corp DE now owns 337,316 shares of the company's stock worth $9,637,000 after buying an additional 248,477 shares during the last quarter. ABC Arbitrage SA grew its holdings in Fresenius Medical Care AG & Co. KGaA by 1,136.0% in the 4th quarter. ABC Arbitrage SA now owns 249,800 shares of the company's stock valued at $5,950,000 after buying an additional 229,589 shares in the last quarter. Finally, Integral Health Asset Management LLC grew its holdings in Fresenius Medical Care AG & Co. KGaA by 44.4% in the 4th quarter. Integral Health Asset Management LLC now owns 650,000 shares of the company's stock valued at $15,483,000 after buying an additional 200,000 shares in the last quarter. 8.37% of the stock is currently owned by hedge funds and other institutional investors.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world's largest integrated provider of products and services for individuals with renal diseases. The company's primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source